Investment
Features
FeesSafety
Academy
More
Pluang+

Sparkasse to offer Bitcoin custody in securities accounts from October, with coins held by the bank, not customers.

Market News
13 Sep 2026
CryptoTicker
View Source
Neutral
Sparkasse to offer Bitcoin custody in securities accounts from October, with coins held by the bank, not customers.

Starting October 2026, Sparkasse will allow customers to buy Bitcoin and other cryptocurrencies held in custody within their securities accounts, meaning the cryptographic keys remain with the bank rather than the customer. This model offers convenience and regulatory protections under EU's MiCAR rules but restricts users from transferring coins to external wallets or participating in staking. Each regional Sparkasse will decide its own launch timing, and investors should verify custodian authorization and understand tax implications before buying. This approach suits beginners and those valuing security and inheritance ease but limits full crypto control.

More News

Jyske Bank buys back shares worth DKK 2.15 billion under 2026 repurchase program

Jyske Bank buys back shares worth DKK 2.15 billion under 2026 repurchase program

Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...

Company Fundamentals
Neutral
37 minutes ago
Jyske Bank buys back shares worth DKK 2.15 billion, now holding 3.84% of its capital.

Jyske Bank buys back shares worth DKK 2.15 billion, now holding 3.84% of its capital.

Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...

Company Fundamentals
Bullish
37 minutes ago
Oculis completes patient randomization in trial for precision treatment of TNFR1-mediated dry eye disease

Oculis completes patient randomization in trial for precision treatment of TNFR1-mediated dry eye disease

Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...

Market News
Bullish
1 hour ago
Ekalia partners with Telix to boost astatine-211 production in the US for cancer therapy.

Ekalia partners with Telix to boost astatine-211 production in the US for cancer therapy.

Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...

Market News
Bullish
2 hours ago
Roche unveils pivotal cancer drug data at ESMO 2026, highlighting advances in lung and breast cancer treatments.

Roche unveils pivotal cancer drug data at ESMO 2026, highlighting advances in lung and breast cancer treatments.

At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App